A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers Meeting Abstract


Authors: Harding, J. J.; Hofheinz, R. D.; Elez, E.; Kuboki, Y.; Rasco, D. W.; Cecchini, M.; Shen, L.; He, M.; Archuadze, S.; Chhaya, N.; Pant, S.
Abstract Title: A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers
Meeting Title: 2023 ASCO Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 41
Issue: 4 Suppl.
Meeting Dates: 2023 Jan 19-21
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2023-02-01
Language: English
DOI: 10.1200/JCO.2023.41.4_suppl.115
PROVIDER: EBSCOhost
PROVIDER: cinahl
DOI/URL:
Notes: Meeting Abstract: 115 -- Accession Number: 161484588 -- Entry Date: In Process -- Revision Date: 20230127 -- Publication Type: Article -- Supplement Title: 2/1/2023 Supplement 1 -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Joseph Harding
    260 Harding